EMERYVILLE, Calif., June 4 /PRNewswire-FirstCall/ — Onyx
Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced updated interim results of
the Phase 1b dose-escalation trial, known as the 006 study,
evaluating carfilzomib in combination with lenalidomide
(Revlimid®) and low dose dexamethasone in patients with
relapsed and/or refractory myeloma. These data are being
presented today at the 46th American Society of Clinical Oncology
(ASCO) Annual Meeting in Chicago
by William Bensinger, M.D.,
Professor of Medicine of the Division of Oncology, Fred Hutchinson
Cancer Research Center at the University of
Washington School of Medicine.
The overall response rate in the cohorts of patients receiving
full doses of the combination was 75 percent in 48 evaluable
patients. Median duration of response has not yet been
reached. No dose-limiting toxicities were observed, and the
maximum tolerated dose was not reached. The maximum
per-protocol doses of 27mg/m2 carfilzomib, 25mg lenalidomide, and
low dose (40mg) dexamethasone were safely administered.
Overall response is measured as a partial response or
greater.(i)
“Nearly all patients with multiple myeloma who receive initial
treatment will eventually relapse and require further therapy,”
said Dr. Bensinger. “Although new agents have been developed
over the past several years, we require additional treatment
options that improve progression-free survival and extend overall
response rates with a tolerability profile that is mild and
manageable. The interim results from this Phase 1b study show
an encouraging efficacy profile in this heavily
‘/>”/>
